SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody based treatments have received emergency use authorization in mild COVID cases in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization.
Copyright © 2024 - Odisha Television Limited All Rights Reserved.